Fredun Pharmaceuticals Limited Unveils Cellular Longetivity Dedicated Platform Daulcel
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Fredun Pharmaceuticals has launched 'DAULCÉL', a premium wellness brand focused on cellular longevity and preventive healthcare using NAD+ science. The company positions this as a strategic entry into the emerging longevity and wellness segment in India. This expands Fredun's portfolio beyond its existing pharmaceutical offerings (antihypertensives, antidiabetic, ARVs, nutraceuticals). Fredun reported FY25 revenues of ₹456 Cr with EBITDA of ₹55 Cr and PAT of ₹21 Cr, indicating a profitable base from which to fund this diversification into premium wellness.
The launch signals strategic diversification into high-growth wellness categories but lacks immediate revenue impact since no orders or commercial details were disclosed. This is a forward-looking brand positioning announcement rather than a concrete near-term earnings catalyst.